ClinicalTrials.gg

Program

Actinium-225

Also written as “[225Ac]Ac-FL-261”, “[225Ac]Ac-AKY-2519 (therapeutic)” and “Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])”.

Its studies are mostly in Prostatic Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell · Triple Negative Breast Neoplasms, led by 6 companies.

Furthest: phase 3, since May 28, 202510 company-led studies, 8 open or runningNext primary completion: Sep 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aktis Oncology33 open or runningphase 1since May 28, 2025May 28, 2025Dec 2027phase 1 · NCT07581184
Alpha-9 Oncology USA21 open or runningphase 1since Jun 27, 2025Jun 27, 2025Dec 2028phase 1 · NCT07661641
AstraZeneca21 open or runningphase 3since Apr 22, 2026Nov 9, 2018Jun 4, 2029phase 3 · NCT07611110
Eli Lilly11 open or runningphase 1since Jan 3, 2024Jan 3, 2024Sep 2027phase 1 · NCT06229366
Full-Life Technologies UK11 open or runningphase 2since Sep 23, 2026Sep 23, 2026Jun 30, 2030phase 2 · NCT07873450
PeptiDream11 open or runningphase 1since Jun 17, 2026Jun 17, 2026May 2029phase 1 · NCT07688187

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2018First study: phase 1 study in Endometrial NeoplasmsNew to AstraZenecaAstraZeneca · NCT03746431 · 78 enrolled · United States, Australia, Canada
  2. Jan 3, 2024Eli Lilly's first study: phase 1 study in Prostatic NeoplasmsNew to Eli LillyEli Lilly · NCT06229366 · 142 enrolled · Canada
  3. May 28, 2025Aktis Oncology's first study: phase 1 study in Triple Negative Breast NeoplasmsNew to Aktis OncologyAktis Oncology · NCT07020117 · 150 planned · United States
  4. Jun 27, 2025Alpha-9 Oncology USA's first study: phase 1 study in Uveal MelanomaNew to Alpha-9 Oncology USAAlpha-9 Oncology USA · NCT07076550 · 5 enrolled · Australia
  5. Apr 22, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedAstraZeneca · NCT07611110 · 670 planned · United States, Australia, Austria and more
  6. May 6, 2026Phase 1 study in Prostatic NeoplasmsAktis Oncology · NCT07581184 · 138 planned · United States
  7. Jun 9, 2026Phase 1 study in Breast NeoplasmsAlpha-9 Oncology USA · NCT07661641 · 115 planned · Australia
  8. Jun 17, 2026PeptiDream's first study: phase 1 study in Carcinoma, Renal CellNew to PeptiDreamPeptiDream · NCT07688187 · 60 planned · United States
  9. Sep 23, 2026Full-Life Technologies UK's first study: phase 2 study in Colorectal NeoplasmsNew to Full-Life Technologies UKFull-Life Technologies UK · NCT07873450 · 208 planned · United States, Australia, China
  10. Oct 15, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungAktis Oncology · NCT07887971 · 152 planned · United States

Ahead

  1. Sep 2027Primary completion: phase 1 study in Prostatic NeoplasmsEli Lilly · NCT06229366
  2. Dec 2027Primary completion: phase 1 study in Prostatic NeoplasmsAktis Oncology · NCT07581184
  3. Dec 2027Primary completion: phase 1 study in Triple Negative Breast NeoplasmsAktis Oncology · NCT07020117
  4. Dec 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungAktis Oncology · NCT07887971

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07887971Carcinoma, Non-Small-Cell Lung · United States1RecruitingAktis OncologyDec 2028152
NCT07873450Colorectal Neoplasms · United States, Australia, China2RecruitingFull-Life Technologies UKJun 30, 2030208
NCT07688187Carcinoma, Renal Cell · United States1RecruitingPeptiDreamMay 202960
NCT07661641Breast Neoplasms · Australia1RecruitingAlpha-9 Oncology USADec 2028115
NCT07581184Prostatic Neoplasms · United States1RecruitingAktis OncologyDec 2027138
NCT07611110Prostatic Neoplasms · United States, Australia, Austria and more3RecruitingAstraZenecaJun 4, 2029670
NCT07076550Uveal Melanoma · Australia1TerminatedAlpha-9 Oncology USAJul 9, 20265
NCT07020117Triple Negative Breast Neoplasms · United States1RecruitingAktis OncologyDec 2027150
NCT06229366Prostatic Neoplasms · Canada1Active, not recruitingEli LillySep 2027142
NCT03746431Endometrial Neoplasms · United States, Australia, Canada1TerminatedAstraZenecaDec 3, 202578

How it is read

Names in the registry

  • “[225Ac]Ac-FL-261”, 3 entries
  • “[225Ac]Ac-AKY-2519 (therapeutic)”, 2 entries
  • “Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])”, 1 entry
  • “[Ac-225]-PSMA-62 (mCRPC)”, 1 entry
  • “[Ac-225]-PSMA-62 (OmHSPC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.